Cel-Sci Corporation (NYSEAMERICAN:CVM) Short Interest Update

Cel-Sci Corporation (NYSEAMERICAN:CVM) was the target of a significant decline in short interest in the month of August. As of August 14th, there was short interest totaling 714,471 shares, a decline of 40.5% from the July 30th total of 1,200,354 shares. Based on an average daily volume of 271,896 shares, the short-interest ratio is presently 2.6 days. Approximately 4.8% of the company’s shares are sold short.

Institutional Investors Weigh In On Cel-Sci

Large investors have recently bought and sold shares of the company. Bank of America Corp DE raised its holdings in Cel-Sci by 2,188.2% in the second quarter. Bank of America Corp DE now owns 40,981 shares of the company’s stock worth $94,000 after purchasing an additional 39,190 shares during the period. Vanguard Group Inc. grew its holdings in shares of Cel-Sci by 59.7% in the 3rd quarter. Vanguard Group Inc. now owns 292,563 shares of the company’s stock valued at $2,692,000 after buying an additional 109,352 shares during the period. US Bancorp DE acquired a new position in shares of Cel-Sci in the 3rd quarter valued at $80,000. HighTower Advisors LLC bought a new stake in shares of Cel-Sci in the 4th quarter valued at $53,000. Finally, Geode Capital Management LLC increased its position in shares of Cel-Sci by 30.3% in the 4th quarter. Geode Capital Management LLC now owns 79,183 shares of the company’s stock valued at $417,000 after buying an additional 18,432 shares in the last quarter. Institutional investors own 12.08% of the company’s stock.

Cel-Sci Trading Down 0.9%

NYSEAMERICAN:CVM traded down $0.01 during mid-day trading on Monday, hitting $1.55. The company had a trading volume of 29,748 shares, compared to its average volume of 262,730. Cel-Sci has a fifty-two week low of $0.89 and a fifty-two week high of $12.68. The business’s fifty day moving average is $1.31 and its two-hundred day moving average is $2.40. The company has a debt-to-equity ratio of 0.35, a quick ratio of 1.42 and a current ratio of 1.48. The firm has a market cap of $27.02 million, a P/E ratio of -0.16 and a beta of 0.63.

Cel-Sci (NYSEAMERICAN:CVM) last posted its earnings results on Friday, August 14th. The company reported ($0.47) earnings per share (EPS) for the quarter.

About Cel-Sci

CEL-SCI Corporation is a biotechnology company focused on the development of immunotherapy products to treat cancer and infectious diseases. Founded in 1983 and headquartered in Vienna, Virginia, the company applies its proprietary LEAPS® (Ligand Epitope Antigen Presentation System) and Multikine® immunotherapy platforms to stimulate the body’s immune response against disease. CEL-SCI operates as a clinical-stage enterprise, working to translate immunological insights into therapeutic candidates.

The company’s lead product candidate, Multikine (leukineferon), is an investigational immunotherapy designed to enhance the immune system’s ability to attack head and neck cancer cells.